सं. / No. 50014/03/2020-CDN

भारत सरकार/Government of India

रसायन एवं उर्वरक मंत्रालय / Ministry of Chemicals and Fertilizers

औषध विभाग/ Department of Pharmaceuticals

शास्त्री भवन, नई दिल्ली/ Shastri Bhawan, New Delhi Dated: 17⁴⁴ April, 2023

Subject: Monthly Summary Report in respect of Department of Pharmaceuticals for the month of March, 2023-reg.

The undersigned is directed to circulate herewith a copy of the Monthly Summary pertaining to the Department of Pharmaceuticals for the month of March, 2023 for information.

(Shamim Uddin Ansari) Under Secretary to the Govt. of India Tel. 011-23387920

To,

- 1. All members of Council of Ministers.
- 2. Vice Chairman, NITI Aayog, Yojana Bhawan, New Delhi.
- 3. The Principal Information Officer, M/o Information and Broadcasting, Shastri Bhawan, New Delhi.

Copy to:

- 1. Secretaries to the Govt. of India, All Ministries/Department.
- 2. The Chairman, UPSC, Shahajahan Road, New Delhi-110069.
- 3. Secretary to President of India (Rashtrapati Ke Sachiv), Rashtrapati Bhawan, New Delhi-110004.
- 4. Secretary to Vice- President of India (Uprashtrapati Ke Sachiv), New Delhi-110004.
- 5. PS to Prime Minister of India, South Block, New Delhi-110004.
- 6. Director, Cabinet Secretariat, Rashtrapati Bhawan, New Delhi-110004.
- 7. Sr. PPS to Secretary (Pharma).
- 8. Director (NIC), Department of Pharmaceuticals, Shastri Bhawan, New Delhi.

Ministry of Chemicals & Fertilizers Department of Pharmaceuticals

1. Important policy decisions taken and major achievements during the month of March 2023:

A. Approval of EFC/ SFC:

(i) EFC in its meeting held on 15th March, 2023 recommended the new scheme on "Promotion of Research and Innovation in Pharma Medtech Sector (PRIP)" with an overall outlay of Rs. 5,000 crore for a period of 5 years, i.e. from 2023-24 to 2027-28. The recommendations of EFC has been approved by the Minister of Chemicals & Fertilizers and Draft Cabinet Note sent for consideration of Empowered technology Group (ETG).

(ii) SFC meeting regarding Scheme for Assistance to Medical Device Clusters for Common Facilities (AMD-CF) was held and approved minutes sent to Ministries/Departments concerned on 31.03.2023.

B. National Pharmaceutical Pricing Authority (NPPA):

Achievements:

(i) Retail prices of 25 new drugs have been fixed during the month of March, 2023 bringing cumulative figure to 2,299 till March, 2023.

(ii) Ceiling price of 170 scheduled formulations have been fixed during the month of March, 2023 bringing cumulative figure to 651 till March, 2023.

(iii) There has been average reduction of 6.73% in ceiling price of scheduled drugs under NLEM 2022. The estimated annual savings in moving annual turnover (MAT) for 651 formulations fixed under NLEM 2022 till 31.03.2023 is Rs. 3532.24 Crore approximately.

(iv) On the basis of Monitoring & Enforcement activities carried out by Enforcement Division, 447 Preliminary Notices (PNs) have been issued.

(v) As a part of COVID drug management monitoring work, following activities were undertaken during the period:

- (a) Inputs on availability of Oseltamivir along with other drugs were presented in the meeting of the COVID Drug Management Committee chaired by Secretary, DoP held on 28.3.2023 through VC.
- (b) Four market availability surveys through Price Monitoring Resource Units (PMRUs) in 17 States/UTs conducted during March, 2023 for COVID Management Drugs as well as six medical devices.

(vi) Under the CAPPM Scheme, two new Price Monitoring and Resource Unit (PMRU)s have been set up in in the month of March– 2023 (Chandigarh and Arunachal Pradesh). With this, Twenty- three (28) PMRU have been set up in the States till date, viz., Kerala,

Gujarat, Odisha, Rajasthan, Punjab, Haryana, Tripura, Nagaland, Uttar Pradesh, Andhra Pradesh, Mizoram, Jammu & Kashmir, Karnataka, Telangana, Maharashtra, Goa, Madhya Pradesh, Chhattisgarh, Jharkhand, Puducherry, West Bengal, Ladakh and Himachal Pradesh, Bihar, Uttarakhand, Meghalaya, Arunachal Pradesh and Chandigarh. Setting up of PMRUs in the other States are in progress.

Further, an interactive webinar on the topic "Guidance on Guidance on effective reporting through IPDMS Software" was organised by NPPA on 28.03.2023 to provide the guidance to PMRUs regarding effective reporting of activities/ data/ reports through IPDMS Software. The PMRUs in the State/ UTs have actively participated in the webinar.

(vii) Total overcharged amount received during March, 2023 is Rs. 65,44,408/-.

C. National Institutes of Pharmaceutical Education & Research (NIPERs):

Major Achievements of NIPERs during the month are as under:

- a. Out of 973 Research papers published during the current financial year, 99 papers have been published in the month of March, 2023.
- b. Out of 43 Patents filed during the current financial year, 9 patents filed in the month of March, 2023.
- c. Out of 40 MoU signed during the current financial year, 6 MoU has been signed in the month of March, 2023.
- d. All NIPERs organized various programmes on Jan Aushadhi Diwas.
- e. NIPER Hajipur organised a two-day National Symposium on "Biological Therapeutics" on March 10-11, 2023.
- f. NIPER Hajipur organised an in-house workshop and training on LC-ICP-MS from March 21-24, 2023.
- g. NIPER-Kolkata organised a product demo session on "JMP Statistical Discovery" on March 2, 2023.
- NIPER-Kolkata, along with CSIR-IICB, Kolkata, and the Society for Molecular Signalling, organised the "8th International Conference on Molecular Signalling and 4th CeSin Symposium: Signalling in Disease Management and Diagnostics" from March 16-18, 2023.
- i. NIPER-Kolkata organised its annual sports and cultural events, SPECTRA-2023," from March 21-22, 2023.
- j. NIPER-Guwahati organised a two-day workshop on Advanced Drug Design and Medicinal Chemistry-23 (ADDMC-23) on March 9-10, 2023.
- k. NIPER-Guwahati conducted Research collaboration with India and Thailand and Expert Interaction with faculty on March 16, 2023.
- NIPER-Guwahati organised Ideathon #3 (Bio-Innovation Challenge) on March 27, 2023.
- m. NIPER Ahmedabad organised a two-day training programme entitled "Capacity Building Program for Food Regulators: A Step Towards Continual Learning" at NIPER–Ahmedabad and NFSU-Gandhinagar on March 13 and 20, 2023, for Drug Regulators of the FDCA.

D. Schemes:

CONTRACTOR CONTRACTOR CONTRACTOR	r of PMBJP	and a second	under	COM			Incentive
Kendra	s functional	PMBJ	P at MRP	(As on 31.	03.2023)	Suvidha	provided in the
		Value	in Rs.			Sanitary	month March,
		Crore	and			Napkins	2023
		saving	to			@ Rs. 1/-	
			common man				
		during				during the month	
		month of March,			4.		
		2023				March,	
						2023	
March 2023	Cumulative	Sale	Saving	Medicines	Surgical		
	(As on	In Rs.	In Rs.				
	31.03.2023)	Construction and the state of t	(Cr.)				
	51.05.2025)	(CI.)	(Approx.)	2			
122	9304	121.19	742	1800	285	1.03 Cr.	29.26 Cr.

(i) Status of Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP):

(ii) Status of PLI Schemes:

S. No.	Name of Sch	eme	Total No. of Application Received*	No. of Applications approved in the month of March 2023	Total no. of applications approved as on date
1.	Production Linked	Round 1	215	0	39
	Incentive Scheme for Bulk Drug (Last EC Meeting held on 24.03.2023 on PLI Bulk Drugs)	Round 2	24	0	08
		Round 3	09	00	03
		Round 4	01	01	01
		Total	249	01	51
2.	Production Linked Incentive Scheme for Medical Device (Last EC Meeting held on 24.03.2023 on Medical Devices)	Round 1	28	0	13
		Round 2	14	0	08
		Round 3	18	05	05
		Total	60	05	26
4	Production Linked I Scheme for Pharma		278	N/A	55

E. International Cooperation:

(i) DoP participated in the 18th India - Australia Joint Ministerial Commission (JMC) meeting on 11.03.2023.

(ii) 1st Meeting of the Technical Committee to explore possibilities to implement a model similar to Jan Aushadhi in Panama by procuring medicines from India was held on 13.03.2023 under the Chairmanship of Joint Secretary, Department of Pharmaceuticals.

(iii) Meeting with Mr. Teodoro Maldonado, Ambassador of Ecuador was held on 20.03.2023 to further explore possibilities w.r.t. sourcing more medicines by Ecuador from India, and discussions about adoption of Pradhan Mantri Jan Aushadhi Pariyojana.

(iv) Meeting with Mr. Lama A. Alabdulwahab, Organizations and International Cooperation, Ministry of Industry and Mineral Resources, Kingdom of Saudi Arabia was organized on 22.03.2023 under chairmanship of JS (NY) from the Indian side wherein possible cooperation in bilateral investments between the two sides was explored.

(v) Status of supply of medicines to Sri Lanka was reviewed on 24.03.2023 with the participation of High Commission of Sri Lanka, MEA and Pharmexcil.

(vi) DoP participated in the IRIGC-TEC Review Meeting Co-Chaired by EAM from Indian side on 06 March 2023. Subsequently, DoP also participated in the Meeting of 24th India-Russia Working Group on Trade & Economic Cooperation (WG-TEC) held on 24th March, 2023 led by Commerce Secretary wherein both sides acknowledged discussions held in the 2nd JWG on Pharmaceuticals Meeting on 21.12.2022 and agreed to take further steps in this regard.

F. FDI inflow approved during this month: NIL

2. Important policy matters held up on account of prolonged inter-ministerial consultations:

NIL

3. No. of cases of 'sanction for prosecution' pending for more than three months:

NIL

4. Particulars of cases in which there has been a departure from the Transaction of Business Rules or established policy of the Government:

NIL

5. Status of ongoing Swachhata Abhiyan (progress under Special Campaign):

The requirement of monthly updation of the SCDPM Portal for the month of March, 2023 has been fulfilled by uploading the information received from various Sections of this Department in the 2.0 version of the SCDPM Portal.

6. Status of Rationalization of Autonomous Bodies:

Completed

7. Information on the specific steps taken by the Ministry/Department for utilization of the Space Technology based tools and applications in Governance and Development:

NIL

8. Vacancy position of senior level appointments in the Ministry/Department, including Autonomous Bodies/PSUs:

(i) Department of Pharmaceuticals:

S. No.	Name of the posts	Sanctioned Strength	In-position	Vacancy	Group
1	Director/DS	06	05	01	А
2	Under Secretary	10	09	01	А
3	Principal Private Secretary	02	0	02	А
4	Section Officer	16	03	13	В
	Total	34	17	17	

(ii) Public Sector Undertakings:

(a) Karnataka Antibiotics & Pharmaceuticals Limited (KAPL):

S. No.	Designation	Vacant Positions
1	Senior Manager	06
2	Deputy General Manager	03
3	General Manager	06
	Total	15

(b) Hindustan Antibiotics Limited (HAL) (under strategic sale):

S.No.	Designation	Vacant Positions	
1	CGM	3	
2	GM	3	
3	DGM	12	
4	Manager	20	
	Total	38	

(c) Bengal Chemicals & Pharmaceuticals Limited (BCPL)(under strategic sale):

S.No.	Designation	Vacant Positions	
1	Manager (Legal)	1	
2	DGM (Marketing)	1	
3	Sr. Manager (Purchase)	1	
4	DGM (Finance)	1	
5	Assistant Manager (Company Secretary)	1	
6	Factory Head (DGM/AGM)	2	
7	AGM (QA/QC)	1	
	Total	8	

(d) Indian Drugs & Pharmaceuticals Limited (IDPL) : NIL

(e) Rajasthan Drugs & Pharmaceuticals Limited (RDPL) :

NIL

9. List of cases in which ACC directions have not been complied with:

NIL

10. Details of FDI proposals cleared during the month and status of FDI proposals awaiting approval in the Ministry/Department:

(i)	Pending at beginning of the month	:	(11)
(ii)	Received during the month	:	(2)
(iii)	Disposed of during the month	:	(1)
(iv)	Pending at end of the month	÷	(12)
	*****	*	